Antithrombins deactivate several enzymes of coagulation system to prevent excessive blood clots. Growing use of antithrombin in conjunction with heparin due to the increased reporting of diseases like sepsis, intravascular coagulations, and myocardial infractions, high incidences of coagulation disorders, increased rates of kidney and heart failure (used extensively in dialysis and open-heart surgeries) are the key drivers of the global antithrombin market. However, because of animal testing restrictions, there is limited research on pipeline drugs being performed is a prominent challenge to the global market. Also, issues including the rising usage of biologics and the high price of antithrombin drugs are limiting the global antithrombin market.

The antithrombin market was pegged at US$ 550 million in 2021. The market is expected to witness a CAGR of 3.90% from 2022 to 2030.

In these circumstances, antithrombins or blood thinners are advised to prevent blood clots, which eventually reduces the risk of heart attack and stroke. Antithrombins acts by preventing the activity of certain clotting factors that are naturally found in blood. These medications are frequently used to stop blood clot (thrombi) formations in veins or arteries.

To access the Sample PDF of this research study, please request here:

Many new developments are also impacting the growth of global antithrombin market. For instance, Antithrombin Kits are developed by Chromogenix Sweden AB. The kit is developed to determine antithrombin activity in human plasma. Apart from traditional thrombin tests, the kit distinguishes between persons who are antithrombin deficient and those who are not. The kit has been modified to work with a variety of automated analyzers, resulting in equivalent response conditions for each analyzer.

Key Players:

Gilead Sciences Inc., Strategic Developments, Bristol-Myers Squibb Company, Novartis International AG, Merck & Co., Shire Plc., Kedrion S.p.A, Scripps Laboratories Inc., Lee Biosolutions Plc., Grifols S.A., and CSL Behring GmbH among others

Segmentation By Application:

  • Therapeutics
  • Research
  • Diagnostics

By Source

  • Human
  • Goat Milk
  • Bovine

Browse the full report now:

Key Questions Answered in the Report Include:

(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3) What are the major global Antithrombin Market trends influencing the development of the market?

(4) What are the vital results of SWOT analysis of the major players operating in the Antithrombin Market?

(5) What are the potential growth opportunities and threats faced by Major competitors in the market?


About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.